{"id":829936,"date":"2026-05-29T11:25:15","date_gmt":"2026-05-29T11:25:15","guid":{"rendered":"https:\/\/www.europesays.com\/us\/829936\/"},"modified":"2026-05-29T11:25:15","modified_gmt":"2026-05-29T11:25:15","slug":"phoenix-and-raven-offer-eligible-canadians-ozempic-at-the-same-price-as-generic-semaglutide","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/829936\/","title":{"rendered":"Phoenix and Raven Offer Eligible Canadians Ozempic\u00ae at the Same Price as Generic Semaglutide"},"content":{"rendered":"<p>    <img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2026\/05\/5e17abae878a1c33a70519115b7fc4a4.jpeg\" alt=\"\" loading=\"eager\" height=\"480\" width=\"480\" class=\"yf-lglytj  loaded\"\/>      <img decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"\" loading=\"lazy\" height=\"480\" width=\"480\" class=\"yf-lglytj loader\"\/>     <\/p>\n<p class=\"yf-1fy9kyt\">The digital health providers are giving Canadians a real choice: Brand-name Ozempic\u00ae at the same starting price at $124.99 as generic semaglutide<\/p>\n<p class=\"yf-1fy9kyt\"><b>TORONTO, May 29, 2026<\/b>&#8211;(<a href=\"https:\/\/www.businesswire.com\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:BUSINESS WIRE;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;BUSINESS WIRE&quot;}\" class=\"link \">BUSINESS WIRE<\/a>)&#8211;<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.phoenix.ca%2F&amp;esheet=54543829&amp;newsitemid=20260529609600&amp;lan=en-US&amp;anchor=Phoenix&amp;index=1&amp;md5=c0e3a09979f7b6fecf5525fc9011f81f\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Phoenix;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Phoenix&quot;}\" class=\"link \">Phoenix<\/a> and <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.getraven.com%2F%3Futm_source%3Dgoogle%26utm_medium%3Dpaidsearch%26utm_campaign%3Drv_bof_branded_tCPA%26utm_term%3Draven%2520health%26utm_content%3D784272321290%26gad_source%3D1%26gad_campaignid%3D23270844874%26gbraid%3D0AAAAA-NIBtQz8s2IsKU8KQGXfhYsN_DXU%26gclid%3DCjwKCAjwt7XQBhBkEiwAtStpp15biD2V_JG0mbfLO4bJWwur-s2VLRJFI4qFInOG5cb_U17Jf1YGeBoCO9kQAvD_BwE&amp;esheet=54543829&amp;newsitemid=20260529609600&amp;lan=en-US&amp;anchor=Raven&amp;index=2&amp;md5=1eb5264f9578a3c959d350172ac91fd9\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Raven;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Raven&quot;}\" class=\"link \">Raven<\/a>, Canada\u2019s leading digital health providers, announced today that eligible Canadians can now access Ozempic\u00ae through their platforms at the same starting $124.99 price as generic semaglutide, giving patients paying out of pocket the freedom to choose based on what\u2019s right for them clinically, without cost being the deciding factor.<\/p>\n<p class=\"yf-1fy9kyt\">&#8220;Last week, we made a commitment to Canadians by leading on competitive pricing for generic semaglutide, and today, we\u2019re proud to go further, extending that same commitment to patients choosing Ozempic\u00ae,&#8221; said <b>Kevin Bache Founder and Co-CEO at Phoenix and Raven<\/b>. &#8220;We\u2019ve turned our promise of accessible, affordable care into reality for patients from coast to coast. Phoenix and Raven are setting a new standard for what Canadian telehealth companies can and should do for patients across the country.&#8221;<\/p>\n<p class=\"yf-1fy9kyt\">Through Phoenix and Raven, the Novo Nordisk savings card rebate will be applied automatically for eligible Ozempic\u00ae prescriptions at checkout, reducing out-of-pocket costs right away. Whether patients are just beginning their treatment journey or want to stay on the brand they already know, this option is designed to help them get started and stay on track. Phoenix and Raven <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20260521867755%2Fen%2FPhoenix-and-Raven-Become-First-Canadian-Telehealth-Platforms-to-Offer-Generic-Semaglutide-Direct-to-Patients&amp;esheet=54543829&amp;newsitemid=20260529609600&amp;lan=en-US&amp;anchor=became+the+first+telehealth+Canadian+platforms&amp;index=3&amp;md5=f9007cd4ba4a87a36109026f8824c6e2\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:became the first telehealth Canadian platforms;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;became the first telehealth Canadian platforms&quot;}\" class=\"link \">became the first telehealth Canadian platforms<\/a> to offer generic semaglutide directly to patients last week, following <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.canada.ca%2Fen%2Fhealth-canada%2Fnews%2F2026%2F04%2Fcanada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html&amp;esheet=54543829&amp;newsitemid=20260529609600&amp;lan=en-US&amp;anchor=Health+Canada%27s&amp;index=4&amp;md5=e541a6628110cfb34e074791fb7643ab\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Health Canada&#039;s;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Health Canada&#039;&quot;}\" class=\"link \">Health Canada&#8217;s<\/a> landmark April 2026 authorization.<\/p>\n<p class=\"yf-1fy9kyt\">&#8220;Today\u2019s announcement means Canadians can now ask for a brand that they know and are familiar with, with the decision no longer being shaped by price,&#8221; said <b>Dr. Mark Broussenko, Medical Director at Phoenix and Raven<\/b>. &#8220;For patients, this changes everything because the conversation can finally just be about what\u2019s right for them clinically, and no longer about accessibility restrictions to Ozempic\u00ae. This is the only conversation that should ever matter and we\u2019re proud to bring the same starting $124.99 pricing to all Canadians.&#8221;<\/p>\n<p class=\"yf-1fy9kyt\">Ozempic\u00ae is available by prescription only, with eligibility determined by a licensed Canadian prescriber. Patients in Canada (excluding Quebec) paying entirely out of pocket can access the Novo Nordisk Ozempic\u00ae savings card automatically through Phoenix and Raven for eligible prescriptions and are encouraged to speak with their provider about whether Ozempic\u00ae is right for them. Visit <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fphoenix.ca&amp;esheet=54543829&amp;newsitemid=20260529609600&amp;lan=en-US&amp;anchor=phoenix.ca&amp;index=5&amp;md5=70fc1777a0cc6351c63f5d083a77b13a\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:phoenix.ca;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;phoenix.ca&quot;}\" class=\"link \">phoenix.ca<\/a> and <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.getraven.com&amp;esheet=54543829&amp;newsitemid=20260529609600&amp;lan=en-US&amp;anchor=getraven.com&amp;index=6&amp;md5=d15360f42b362fc27179fbc7131a5e3f\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:getraven.com;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;getraven.com&quot;}\" class=\"link \">getraven.com<\/a> to learn more.<\/p>\n<p class=\"yf-1fy9kyt\"><b>ABOUT PHOENIX &amp; RAVEN<\/b><\/p>\n<p class=\"yf-1fy9kyt\">Phoenix is Canada\u2019s leading digital health clinic for men, specializing in three areas of treatment \u2013 erectile dysfunction, weight loss, and hair loss. Phoenix also launched Raven, a telehealth platform built to support women through every stage of their health journey, tailored to their needs, including treatments for weight loss, and hair loss. Both platforms facilitate access to licensed Canadian prescribers, treatment options, and free, discreet shipping of prescription medication from coast to coast. Visit <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fphoenix.ca&amp;esheet=54543829&amp;newsitemid=20260529609600&amp;lan=en-US&amp;anchor=phoenix.ca&amp;index=7&amp;md5=d8dcab41e5cf48edc3eb1c9e6ec7df3d\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:phoenix.ca;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;phoenix.ca&quot;}\" class=\"link \">phoenix.ca<\/a> and <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.getraven.com&amp;esheet=54543829&amp;newsitemid=20260529609600&amp;lan=en-US&amp;anchor=getraven.com&amp;index=8&amp;md5=a9ca30bc2835f1e2f698f777f49328e4\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:getraven.com;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;getraven.com&quot;}\" class=\"link \">getraven.com<\/a> to learn more.<\/p>\n<p class=\"yf-1fy9kyt\">View source version on businesswire.com: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260529609600\/en\/\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:https:\/\/www.businesswire.com\/news\/home\/20260529609600\/en\/;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;https&quot;}\" class=\"link \">https:\/\/www.businesswire.com\/news\/home\/20260529609600\/en\/<\/a><\/p>\n<p class=\"yf-1fy9kyt\"><b>Contacts<\/b><\/p>\n<p class=\"yf-1fy9kyt\"><b>MEDIA CONTACT <\/b><\/p>\n<p>Kayla Moyes<br \/>Director of Corporate Communications, Talk Shop Media<br \/><a href=\"https:\/\/finance.yahoo.com\/sectors\/healthcare\/articles\/mailto:kayla.moyes@talkshopmedia.com\" rel=\"nofollow noopener\" data-ylk=\"slk:kayla.moyes@talkshopmedia.com;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;kayla.moyes@talkshopmedia.com&quot;}\" class=\"link \" target=\"_blank\">kayla.moyes@talkshopmedia.com <\/a><br \/>250-218-9276<\/p>\n","protected":false},"excerpt":{"rendered":"The digital health providers are giving Canadians a real choice: Brand-name Ozempic\u00ae at the same starting price at&hellip;\n","protected":false},"author":3,"featured_media":829937,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[5131],"tags":[5229,5643,1587,340632,18301,1589,226740,340631,67,586,132,5230,68,2969],"class_list":["post-829936","post","type-post","status-publish","format-standard","has-post-thumbnail","category-phoenix","tag-america","tag-arizona","tag-az","tag-novo-nordisk-ozempic","tag-patients","tag-phoenix","tag-raven","tag-telehealth-companies","tag-united-states","tag-united-states-of-america","tag-unitedstates","tag-unitedstatesofamerica","tag-us","tag-usa"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116657620918378256","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/829936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=829936"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/829936\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/829937"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=829936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=829936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=829936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}